Annexin A3 is a member of the lipocortin/annexin family, which binds to phospholipids and membranes in a Ca 2؉ -dependent manner. Although annexin A3 has various functions in vitro, its cellular significance is completely unknown. Annexin A3 is not found in rat liver in vivo. In the present study, we investigated the expression of annexin A3 in primary cultured parenchymal rat hepatocytes. Annexin A3 protein was detected in 48-h, but not 2.5-h, cultured hepatocytes using Western blot analysis. The annexin A3 level further increased after an additional 24 h of culture. Annexin A3 mRNA was not detected in 2.5-h cultured hepatocytes but was detected 22 h after the start of culture by RT-PCR analysis, reaching a maximum value after 48 h of culture. To define the role of Annexin A3 in DNA synthesis, RNA interference was used to reduce annexin III gene expression in hepatocytes. The transfection of small interfering RNAs targeting annexin A3 in the hepatocytes reduced the corresponding mRNA and protein expression by approximately 80% and more than 90%, respectively, at 24 h after transfection. In the annexin A3 small interfering RNAs-transfected cells, DNA synthesis, as assessed by [ 3 H]thymidine incorporation, decreased by approximately 70% not only in the control cultures, but also in the hepatocyte growth factor-or epidermal growth factor-treated cells. These findings show that annexin A3 is expressed in primary cultured parenchymal rat hepatocytes and that the suppression of annexin A3 expression using RNA interference inhibits DNA synthesis.
2ϩ
-dependent manner. [2] [3] [4] AnxA3 has been shown to have anticoagulant and anti-phospholipase A 2 properties in vitro 5) and to promote the Ca 2ϩ -dependent aggregation of isolated specific granules from human neutrophils. 6) Although the physiological functions of other annexins have been recently clarified in knock-out and transgenic models, [7] [8] [9] [10] [11] [12] [13] [14] the functions of AnxA3 are completely unknown. 15) Recently, we found that AnxA3 protein and its mRNA are not expressed in isolated parenchymal rat hepatocytes. 16, 17) Consistent with these findings, AnxA3 protein and its mRNA are not detectable by Western blot analysis and Northern blot analysis in rat liver. [18] [19] [20] [21] However, there have been no reports on the behavior of AnxA3 in primary cultured parenchymal rat hepatocytes. In the present study, we investigated the expression and function of AnxA3 in cultured parenchymal rat hepatocytes.
MATERIALS AND METHODS

Materials
Recombinant human hepatocyte growth factor (HGF) was purchased from R&D systems (Minneapolis, MN, U.S.A.). Mouse epidermal growth factor (EGF) was purchased from Wako (Osaka, Japan). [ Cell Isolation and Monolayer Cultures Parenchymal hepatocytes were isolated from adult male Wistar rats, weighing 180-200 g, by in situ perfusion of the liver with collagenase. 22) All animal care and procedure protocols were approved by the institutional care committee. The cells were then suspended at a density of 2.5ϫ10 5 cells/ml in Williams E medium (WE) containing 5% fetal bovine serum and 1 nM insulin and cultured at a density of 0.5ϫ10 5 cells/cm 2 in a 6 cm dish and a 48-well microplate precoated with collagen type-1 AC in a humidified chamber at 37°C in 5% CO 2 and 30% O 2 in air. Cells plated in the 6-cm dish and 48-well microplate were used to prepare total cellular extracts or total RNA and to measure DNA synthesis, respectively. After 2.5 h of culture, the medium was replaced with a serum-and hormone-free medium containing aprotinin (1 mg/ml).
Western Blot Analysis Cell lysates were prepared using a modification of a previously described method.
23) The cells were washed with phosphate-buffered saline (PBS) followed by buffer A (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, and 10 mM EDTA). The cells were then harvested after the addition of 20 ml of buffer A. The cells were suspended, shaken for 15 min at room temperature, and sonicated five times for 15 s each time while in an ice bath after the addition of 1/5 [v/v] of 5ϫbuffer A containing 2.5% Triton X-100 and 1/100 [v/v] of a protease inhibitor cocktail (SIGMA). After centrifugation at 100000ϫg, the cytosolic fraction (about 25 mg) was subjected to sodium dodecyl sulfate-polyacrylamide gel 20 in a final volume of 40 ml, according to the manufacturer's protocols. Subsequently, 1 ml of cDNA was polymerase chain reaction (PCR)-amplified using the THERMOSCRIPT TM RT-PCR System (Invitrogen) in a final volume of 20 ml per reaction, according to the manufacturer's protocols, for 14-23 cycles of denaturation for 30 s at 94°C, annealing for 30 s at 60°C, and polymerization for 1 min at 72°C using Anx AIII or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA specific primers under linear conditions. The PCR products were separated on a 2% agarose gel, stained with SYBR Green I, and visualized and analyzed with a FluoroImager 595 (Amersham Bioscience). A computer assisted-analyzer was used to quantitatively analyze the signals, and the signals were normalized to the signal of a house keeping gene, the gene coding GAPDH. The sequences of the AnxA3 primers were as follows: 5Ј-CAAATTCACCGAGATCCTGT-3Ј and 5Ј-TGCTGGAGTGCTGTACGAAA-3Ј. The sequences of the GAPDH primers were as follows: 5Ј-ACCACAGTCCAT-GCCATCAC-3Ј and 5Ј-TCCACCACCTGTTGCTGTA-3Ј. 24) The PCR product specificity was confirmed by DNA sequence analysis using an ABI Prism 377 DNA Sequencer (Applied Biosystems, Foster City, CA, U.S.A.).
Preparation and Transfection of Small Interfering RNAs Targeting AnxA3
Small interfering RNAs (siRNAs) targeting rat AnxA3 were designed according to the guidelines of the "Dharmacon siDESIGN Center" (www.dharmacon.com) and obtained from Dharmacon Research (Lafayette) in annealed and lyophilized forms. The target sequences were localized at positions, 493 and 690 bps downstream of the start codon. The sequences of each siRNA pair were as follows: AnxA3 siRNA 1, 5Ј-GAG ACG AAA GCC UGA AAG UdTdT-3Ј and ACU UUC AGG CUU UCG UCU cdTdT-3Ј; ANXA3 siRNA 2, 5Ј-GGA GAA UUA UCU GGG CAU UdTdT-3Ј and AAU GCC CAG AUA AUUCUC cdTdT-3; and control siRNA, 5Ј-ACU CUA UCU GCA CGC UGA CUU-3Ј and 5Ј-P G UCA GCG UGC AGA UAG AGU UU-3Ј. No homology between any relevant mammalian gene and the control siRNA was observed. These siRNAs were dissolved in an RNase-free solution provided by Dharmacon Research at a concentration of 20 mM. After 20 h of cell culture, the medium was replaced with WE containing aprotinin (1 mg/ml) immediately prior to transfection. Transfection with siRNA was performed using SiFector (Bbridge), according to the user guidelines. Sixty microliters of both AnxA3 siRNA 1 and 2 were diluted with OPTI-MEM (Invitrogen) to a final volume of 400 ml. Sixty-four microliters of SiFector was also diluted in OPTI-MEM to a final volume of 400 ml, then suspended and incubated at room temperature for 5 min. Next, the diluted siRNA was combined with SiFector, and the mixture was incubated at room temperature to allow the siRNA-SiFector complex to form. Eight hundred microliters of the siRNA-SiFector complex was added to the cultures (6-cm dish). For the 48-well plates, the siRNA-SiFector complex was prepared as described above except that the volume of each solution per well was scaled down to 1/16.
Measurement of [
3 H]thymidine Incorporation After 20 h of culture, the medium was replaced with hormone-free medium containing aprotinin (1 mg/ml) and 0.1% bovine serum albumin (BSA), and EGF (2 ng/ml) or HGF (20 ng/ml) was added. After 1 h, 50 ml of siRNA-SiFector complex, prepared as described above, was added to the wells. After another 24 h, [ 3 H]thymidine (0.626 mCi) and thymidine (676.6 ng) were added, and 10 mg/ml of aphidicolin was added to some wells at the same time. The cells were then cultured for another 24 h. [ 3 H]thymidine incorporation was measured as described previously. 25) The difference between the radioactivity in the hot-trichloroacetic acid soluble fraction with and without aphidicolin was calculated as dpm/mg protein.
Cell protein was measured using a previously described method, 26) with BSA used as a standard.
RESULTS
Expression of AnxA3 during Culture
At first, we investigated the expression of AnxA3 in primary cultured parenchymal rat hepatocytes. AnxA3 protein was not detected by Western blot analysis 2.5 and 24 h after the start of culture but was detected after 48 h of culture (Fig. 1A) . The level after 72 h of culture was approximately 1.6-fold higher than that after 48 h of culture (Fig. 1B) . AnxA3 mRNA was not detected by reverse transcription (RT)-PCR in cultured hepatocytes after 2.5 h of culture but was significantly detected after 22 h of culture ( Fig. 2A) , reaching a maximum value after 48 h of culture (Fig. 2B) . These results indicate Suppression of AnxA3 Expression Using RNA Interference Next, we attempted to suppress AnxA3 expression by RNA interference (RNAi) to examine the role of ANXA3 in the cultured hepatocytes. AnxA3 mRNA expression was markedly reduced by treatment with AnxA3 siRNAs, compared with the expression after treatment with control siRNA, 1 d after the transfection (Fig. 3A) , with an inhibition of approximately 80% (Fig. 3B) . Furthermore, the AnxA3 protein level was also reduced by the treatment with AnxA3 siRNAs compared with the level after treatment with control siRNA (Fig. 4A) , with an inhibition of more than 95% (Fig.  4B) . On the other hand, the control siRNA had almost no effect on AnxA3 protein and mRNA levels compared with those treated with SiFector alone (data not shown). Neither the control nor AnxA3 siRNAs caused any cytotoxic effects, as observed microscopically or by the quantification of the total amount of protein in each sample (data not shown). These results indicate that AnxA3 siRNAs efficiently and specifically, inhibit the expression of AnxA3 in primary cultured parenchymal rat hepatocytes.
Inhibition of DNA Synthesis by Suppression of AnxA3 Expression Using RNAi Finally, we examined the role of AnxA3 in DNA synthesis by suppressing AnxA3 expression using RNAi. EGF (2 ng/ml) and HGF (20 ng/ml) stimulated DNA synthesis by approximately 7-fold and 9-fold, respectively in hepatocytes treated with control siRNA (Fig. 5) . The stimulations were inhibited to approximately 70% by treatment with AnxA3 siRNAs. Similar results were also obtained in the control cells, whereas the control siRNA had almost no effect on DNA synthesis, compared with the effect in cells treated with SiFector alone (data not shown).
DISCUSSION
In the present study, we showed for the first time that AnxA3 is expressed in cultured parenchymal rat hepatocytes and that the inhibition of AnxA3 expression by RNAi resulted in a significant inhibition of DNA synthesis, suggesting that the expression of AnxA3 is necessary for DNA synthesis in primary cultured parenchymal rat hepatocytes.
Hepatocytes placed under culture conditions, are known to acquire a growth potential characterized by the enhancement of DNA synthesis, which is caused by several growth factors. 27, 28) Our present findings suggest that the expression of AnxA3 is partly necessary for hepatocytes to acquire a growth potential under culture conditions. In fact, the enhanced expression of AnxA3 has been observed in hepatocellular carcinoma cell lines. 29) In addition, we discovered that the enhanced expression of Anx3 was observed in the proliferative hepatocytes after carbon tetrachloride-induced rat liver damage (unpublished observations).
As for other annexins, several findings concerning the relation of AnxA1 to hepatocyte growth has been reported as described below. The suppression of AnxA1 expression using antisense technology inhibited proliferation in a mouse hepatocyte cell line. 30) AnxA1 increased in the proliferative hepatocytes after carbon tetrachloride-induced rat liver damage or a partial hepatectomy and in hepatocellullar carcinoma tissue. 31, 32) Although the mechanism of action of AnxA3 on DNA synthesis is presently uncertain, the target of AnxA3 may be a common signal transduction pathway, and not necessarily a constitutive or growth factor-mediated one, because the suppression of AnxA3 expression using RNAi not only inhibited the control of DNA synthesis, but also EGF-or HGF-stimulated DNA synthesis, almost to a similar level. In this respect, the findings described below may be relevant to speculations on the mechanism of action of AnxA3 on DNA synthesis. The growth factor-mediated enhancement of hepatocyte growth consists of several signal transduction pathways. 33) The activation of cytosolic phospholipase A 2 (cPLA 2 ) by MAP kinase liberates arachidonic acid from phospholipids and is followed by the generation of prostaglandins, mediators of DNA synthesis, via cyclooxygenase. Interestingly, the suppression of AnxA1 expression using antisense technology inhibited cPLA 2 activity in a mouse hepatocyte cell line. 30) This report suggests that cPLA 2 must be phosphorylated by AnxA1 to become active. Additional evidence suggests that AnxA1 (275-346 aa), the region responsible for phospholipid binding is necessary for the interaction between AnxA1 and cPLA 2 . 34) Further study is required to clarify the mechanism of action of AnxA3, including the possibility that AnxA3 positively modulates cPLA 2 activity, as in the case of AnxA1. 
